论文部分内容阅读
严重急性呼吸综合征(SARS)是一种新出现的传染性疾病。目前SARS的治疗主要采用维持生命体征的对症治疗。2003年 5月国家药品监督管理局批准将弹性蛋白酶抑制剂———西维来司钠(批号 20030503 )作为用于SARS治疗的试验用药。本研究采用随机开放、平行对照、多中心临床研究,
Severe Acute Respiratory Syndrome (SARS) is a newly emerging infectious disease. The current treatment of SARS is mainly used to maintain the vital signs of symptomatic treatment. In May 2003, the State Drug Administration approved the use of stillaverin (batch No. 20030503), an elastase inhibitor, as a test drug for the treatment of SARS. This study used a randomized open, parallel control, multicenter clinical study,